Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + venetoclax arm for progressive IDH1-mutated acute myeloid leukemia in the AMLM26 INTERCEPT platform
ACTRN12624000141549Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ivosidenib and venetoclax in acute myeloid leukemia (AML) (2 cohorts), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Jun 2026; status: recruiting.
02
Drugs
ivosidenibvenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12624000141549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000141549.